Non-Functional Pancreatic Neuroendocrine Tumors (PNETs) with Transformation to Insulinoma: An Esoteric Presentation of a Rare Disease Abstract #952

Introduction: Most pNETs are usually non-functioning. Rarely, a non-functioning tumor can undergo biological transformation to a functioning tumor with subsequent changes in its clinical features.
Aim(s): We present here two patients with longstanding pNETs who developed severe hyperinsulinemic hypoglycemia in parallel with tumor progression.
Materials and methods:
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Msc Avital Nahmias
Keywords: pNET, everolimus

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1086 mTOR Down-Stream Signaling Pattern May Predict pNET Response to Everolimus
Introduction: NETs are rare neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The mammalian target of rapamycin (mTOR) pathway plays a central role in the regulation of cell growth, metabolism, and apoptosis representing a novel molecular target. This pathway is constitutively activated in pancreatic NETs (pNETs) providing the basis for the development of specific mTOR inhibitors as new therapeutic tools.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PhD student Simona Falletta
Keywords: pNET, Everolimus, mTOR
#1224 A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial
Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Matthew H Kulke
#840 Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Rossana Berardi
#1196 CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)
Introduction: EVE is an mTOR inhibitor (mTORi) approved for the treatment of advanced pNETs. BEZ235, a dual mTOR/PI3K inhibitor, may provide greater PI3K pathway inhibition and enhanced antitumor effects.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Steven Libutti
Keywords: pNET, BEZ235, everolimus
#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi